Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications
The appearance of tyrosine kinase inhibitors (TKIs) has been a major breakthrough in renal cell carcinoma (RCC) therapy. Unfortunately, a portion of patients with TKIs resistance experience disease progression after TKIs therapy. Epigenetic alterations play an important role in the development of TK...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2020.562868/full |
id |
doaj-e98a0c405e2f459d90d89ea29610dd9f |
---|---|
record_format |
Article |
spelling |
doaj-e98a0c405e2f459d90d89ea29610dd9f2021-01-12T05:49:23ZengFrontiers Media S.A.Frontiers in Genetics1664-80212021-01-011110.3389/fgene.2020.562868562868Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical ApplicationsQinhan LiZhenan ZhangYu FanQian ZhangThe appearance of tyrosine kinase inhibitors (TKIs) has been a major breakthrough in renal cell carcinoma (RCC) therapy. Unfortunately, a portion of patients with TKIs resistance experience disease progression after TKIs therapy. Epigenetic alterations play an important role in the development of TKIs resistance. Current evidence suggests that epigenetic alterations occur frequently in RCC patients with poor response to TKIs therapy, and modulation of them could enhance the cytotoxic effect of antitumor therapy. In this review, we summarize the currently known epigenetic alterations relating to TKIs resistance in RCC, focusing on DNA methylation, non-coding RNAs (ncRNAs), histone modifications, and their interactions with TKIs treatment. In addition, we discuss application of epigenetic alteration analyses in the clinical setting to predict prognosis of patients with TKIs treatment, and the potential use of epigenetics-based therapies to surmount TKIs resistance.https://www.frontiersin.org/articles/10.3389/fgene.2020.562868/fullrenal cell carcinomaepigeneticsmicroRNAlong non-coding RNAmethylationhistone modification |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qinhan Li Zhenan Zhang Yu Fan Qian Zhang |
spellingShingle |
Qinhan Li Zhenan Zhang Yu Fan Qian Zhang Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications Frontiers in Genetics renal cell carcinoma epigenetics microRNA long non-coding RNA methylation histone modification |
author_facet |
Qinhan Li Zhenan Zhang Yu Fan Qian Zhang |
author_sort |
Qinhan Li |
title |
Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications |
title_short |
Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications |
title_full |
Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications |
title_fullStr |
Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications |
title_full_unstemmed |
Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications |
title_sort |
epigenetic alterations in renal cell cancer with tkis resistance: from mechanisms to clinical applications |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Genetics |
issn |
1664-8021 |
publishDate |
2021-01-01 |
description |
The appearance of tyrosine kinase inhibitors (TKIs) has been a major breakthrough in renal cell carcinoma (RCC) therapy. Unfortunately, a portion of patients with TKIs resistance experience disease progression after TKIs therapy. Epigenetic alterations play an important role in the development of TKIs resistance. Current evidence suggests that epigenetic alterations occur frequently in RCC patients with poor response to TKIs therapy, and modulation of them could enhance the cytotoxic effect of antitumor therapy. In this review, we summarize the currently known epigenetic alterations relating to TKIs resistance in RCC, focusing on DNA methylation, non-coding RNAs (ncRNAs), histone modifications, and their interactions with TKIs treatment. In addition, we discuss application of epigenetic alteration analyses in the clinical setting to predict prognosis of patients with TKIs treatment, and the potential use of epigenetics-based therapies to surmount TKIs resistance. |
topic |
renal cell carcinoma epigenetics microRNA long non-coding RNA methylation histone modification |
url |
https://www.frontiersin.org/articles/10.3389/fgene.2020.562868/full |
work_keys_str_mv |
AT qinhanli epigeneticalterationsinrenalcellcancerwithtkisresistancefrommechanismstoclinicalapplications AT zhenanzhang epigeneticalterationsinrenalcellcancerwithtkisresistancefrommechanismstoclinicalapplications AT yufan epigeneticalterationsinrenalcellcancerwithtkisresistancefrommechanismstoclinicalapplications AT qianzhang epigeneticalterationsinrenalcellcancerwithtkisresistancefrommechanismstoclinicalapplications |
_version_ |
1724340821452390400 |